Engineered T-Cell Therapy

Engineered T cells are the result of turning a therapeutic process into a product capable of overcoming checkpoint inhibition, and are the future of adoptive immunotherapy. Cytokine release syndrome,” a storm of molecules generated as the cells fights the cancer. Instead of an antibody, single-chain target domain, he used a human cytokine, IL-13, with a mutation in the sequence that gave high affinity for IL-13 receptor α2. These cells were infused intra cranially, establishing the safety of intracranial administration with some antitumor responses.

 

    Related Conference of Engineered T-Cell Therapy

    November 21-22, 2019

    World Conference on Vaccine and Immunology

    MENA Plaza Hotel Albarsha | Dubai, UAE
    November 21-22, 2019

    14th International Conference on Allergy and Clinical Immunology

    Courtyard by Marriot Bali Seminyak Resort | Bali, Indonesia
    December 02-03, 2019

    10th International Conference on Immunology & Immunogenetics

    Park Inn by Radisson Hotel & Conference Centre London
    June 23-24, 2020

    34th World Congress on Vaccines and Immunization

    Osaka, Japan
    September 14-15, 2020

    35th World Congress on Immunology

    Tokyo, Japan
    Oct 12-13, 2020

    International Conference on Vaccine and Vaccine Research

    Manila, Philippines
    October 14-15, 2020

    13th International Conference on Allergy & Immunology

    Zurich, Switzerland
    October 19-20, 2020

    lifestylemanagment-cs-2020

    Amsterdam, Netherlands

    International Conference on Immunology & Immunotherapies

    November 18-19, 2020 | Bangkok, Thailand
    November 25-26, 2020

    International Conference On European Immunology

    London, UK

    Engineered T-Cell Therapy Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in